Breast Cancer Clinical Trials in Chapel Hill, North Carolina

28 studies are recruiting for breast cancer in Chapel Hill, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

   This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/hormone receptor-negative (ER+/HR-) and triple-negative (TN) metastatic breast cancer (MBC). The trial integrates both retrospective and prospec…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

   Locations

   6 in total

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07340541 on ClinicalTrials.gov

2. Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

   Radiation therapy is an essential treatment for tumors in the chest area, including breast, lung, esophageal, mediastinal cancers, and spine metastases. Although technical advances have reduced treatment-related illness and death, radiation exposure to the heart can still cause substantial rates of…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07685938 on ClinicalTrials.gov

3. Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study

   Phase 4 of the Carolina Breast Cancer Study (CBCS4) builds on prior phases that examined molecular and epidemiologic differences in breast cancer types and outcomes. Previous findings showed that certain breast cancer subtypes and genetic factors are linked to higher risks. While prior research unc…

   Stage

   Not phased

   Ages

   20 to 74

   Site

   University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07214610 on ClinicalTrials.gov

4. Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)

   This study evaluates the rates of radiation-specific toxicity, quality of life, and oncologic outcomes for early-stage breast cancer and ductal carcinoma in situ treated with 5-fraction whole breast irradiation (WBI) with a simultaneous integrated tumor bed boost (SIB). SIB refers to the technique …

   Stage

   Phase 2

   Ages

   50 and older

   Site

   University of North Carolina, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT06902311 on ClinicalTrials.gov

5. Dissemination of BREASTChoice AIM1-B

   This registration covers only Aim 1b, which focuses on testing usability. The study will include 20 participants who are breast cancer patients. Participants will be observed using the tool on their mobile devices, and their experience will be evaluated using a "think-aloud" method to capture their…

   Stage

   Not phased

   Ages

   18 and older

   Site

   The University of North Carolina, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07396766 on ClinicalTrials.gov

6. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

7. Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

   The purpose of this study is to determine how circulating tumor DNA (ctDNA), a sign of minimal residual disease (MRD), is detectable after surgery in patients with early HR+/HER2- breast cancer that has spread to 1-3 lymph nodes. Researchers aim to understand if ctDNA detection can identify patient…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07025785 on ClinicalTrials.gov

8. TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

   The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HE…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of North Carolina, Chapel Hill, North Carolina

   Locations

   11 in total

   Run by

   Ana C Garrido-Castro, MD

   See if you can join NCT06533826 on ClinicalTrials.gov

9. A Novel Approach Utilizing Organ Specific Age Proteomics

   This study compares changes in P16INK4A expression and plasma proteomic signatures of specific organ age pre- and post-chemotherapy in women treated with adjuvant chemotherapy for early-stage breast cancer. It aims to determine if biological and accelerated immune aging, assessed using T cells from…

   Stage

   Not phased

   Ages

   22 to 66

   Site

   University of North Carolina, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT06789653 on ClinicalTrials.gov

10. Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

    This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of North Carolina, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06347068 on ClinicalTrials.gov

11. PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

    This is a hybrid decentralized, single-arm, interventional study designed to evaluate the impact of precision medicine navigation and reflexive expert review of next-generation sequencing (NGS) for patients with stage IV solid tumor malignancies (breast, lung, colorectal, and bladder cancers). The …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06896162 on ClinicalTrials.gov

12. Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior

    RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research st…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT01000883 on ClinicalTrials.gov

13. Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

    This is a 4-arm, single-center study involving 40 participants. Ten healthy volunteers will be enrolled for system imaging optimization, and thirty (30) patients with previously identified lesions in the breast, liver, or kidney-based on prior ultrasound or cross-sectional imaging-will be imaged. R…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The University of North Carolina, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT07225114 on ClinicalTrials.gov

14. VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients

    Purpose: This study will evaluate how measurements of tissue stiffness, viscosity, and anisotropy using non-invasive ultrasound imaging correlate with breast tumor malignancy and response to chemotherapy. Participants: Up to 200 women with benign or malignant breast tumors for arm 1 and up to 50 wo…

    Stage

    Not phased

    Ages

    20 to 90

    Site

    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06878547 on ClinicalTrials.gov

15. Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy

    The aim of this prospective study is to investigate quality of life and oncologic outcomes in low-risk elderly breast cancer patients randomized to adjuvant therapy with accelerated partial breast irradiation (APBI) alone or endocrine therapy alone after lumpectomy. The study population will includ…

    Stage

    Phase 2

    Ages

    65 and older

    Site

    University of North Carolina, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT05472792 on ClinicalTrials.gov

16. Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

    This pilot interventional study evaluates the change from baseline to post-intervention in resilience and other patient-reported outcomes for individuals with a recent diagnosis of metastatic breast cancer (MBC) participating in the Promoting Resilience in Women with Breast Cancer (PRISM) intervent…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of North Carolina, Chapel Hill, North Carolina

    Locations

    2 in total

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06855654 on ClinicalTrials.gov

17. Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

    This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomar…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06727773 on ClinicalTrials.gov

18. Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

    This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

    Locations

    15 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04468061 on ClinicalTrials.gov

19. Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

    This is a prospective radiation dose-finding, phase 2 expansion study of the Triple Negative (TN) cohort of the multicenter randomized study P-RAD (A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer; NCT044…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of North Carolina, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT07276880 on ClinicalTrials.gov

20. PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

    This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II/III after conventional neoadjuvant chemo-immunotherapy followed by surgery. Technological advance…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT07069595 on ClinicalTrials.gov

21. PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients

    The purpose of this study is to provide prospective evidence in the US population of the frequency of skin discoloration and Sentinel Lymph Node detection rate in patients who have recevied Magtrace for Sentinel Lymph Node Biopsy (SLNB) and to evaluate the impact that skin discoloration has on pati…

    Stage

    Not phased

    Ages

    18 and older

    Site

    UNC, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Locations

    2 in total

    Run by

    Endomagnetics Ltd.

    See if you can join NCT06610539 on ClinicalTrials.gov

22. Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

    The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Univeristy of North Carolina at Chapel Hill, Chapel Hill, North Carolina

    Locations

    7 in total

    Run by

    Carevive Systems, Inc.

    See if you can join NCT05974150 on ClinicalTrials.gov

23. Nutrition Awareness Among Women With Non-Metastatic Breast Cancer

    This study explores perspectives of women with non-metastatic breast cancer regarding their willingness and ability to make dietary changes pertaining to foods/food products that may pose a risk to their cancer prognosis and survival. This is a single-group study conducted entirely online. All stud…

    Stage

    Not phased

    Ages

    18 and older

    Site

    UNC Cancer Hospital, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT07389967 on ClinicalTrials.gov

24. Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

    The HARMONY trial is an interventional trial enrolling metastatic breast cancer (MBC). Current treatment of breast cancer uses clinical subtype information (e.g. hormone receptor-positive (HR+)) to help guide treatment options. Breast cancer can also be characterized by molecular subtype, but it is…

    Stage

    Not phased

    Ages

    18 to 99

    Site

    UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Locations

    2 in total

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT03769415 on ClinicalTrials.gov

25. Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise

    This study will examine unmet exercise needs among patients with metastatic breast cancer (MBC) at UNC and assess whether participation in Get Real and Heel (GRH) can increase physical activity. The proposed research aims to improve multiple domains of well-being, quality of life, physical function…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Lineberger Comphrehensive Cancer Center at University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT07313306 on ClinicalTrials.gov